Literature DB >> 6366179

beta 2-microglobulin in non-malignant and malignant human breast: a feature of differentiation.

K Sidky, R A Walker.   

Abstract

An indirect immunofluorescent method has been used to study the distribution of the membrane protein beta 2-microglobulin in normal, benign and malignant human breast tissue. A uniform staining of epithelial cell membranes has been found in all normal and benign tissues, with only a minor variation in the intensity of reaction between samples. In contrast the carcinomas have shown a variety of reactions, with some behaving in a manner similar to the normal and benign breast tissue, others being heterogeneous with regard to intensity of staining and the remainder having a weak or a negative reaction. The immunohistochemical behaviour of the carcinomas has paralleled the degree of histological differentiation, with poorly differentiated carcinomas showing little reactivity. A comparable relationship with lymph node status has not been found. Although those carcinomas with a staining pattern akin to non-malignant tissue have a lower incidence of lymph node metastasis it has been the heterogeneous reacting group rather than the weak staining and negative tumours which has shown a higher rate of axillary lymph node metastasis. The prognostic significance of this finding is at present uncertain and can probably only be assessed from information about patient survival.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6366179     DOI: 10.1002/path.1711420204

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  2 in total

1.  Serum beta 2-microglobulin in chronic diseases of the pancreas.

Authors:  R Pezzilli; P Billi; M Fiocchi; E Beltrandi; O Cappelletti; G Sprovieri; M Miglioli
Journal:  Int J Pancreatol       Date:  1995-04

2.  Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.

Authors:  H O Wintzer; M Benzing; S von Kleist
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.